Little Green Pharma Ltd (lgp) Logo

Little Green Pharma Ltd (LGP)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

LGP Chart

Snapshot

LGP's Principal Activity is the cultivation of medicinal Cannabis, procurement of raw materials and the production of medicinal cannabis medicines, establishment and continued development of distribution pathways within Australia, the EU and other international jurisdictions and ongoing research and development into new medicinal cannabis products and delivery technologies.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -10.52%
vs ASX 200 (1yr) -19.31%

Size

Market Capitalisation
ASX Rank 1,083 of 2,400
Sector Rank 88 of 207

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies CAN / MXC / QTM
EPS $0.16
DPS $0.00
NTA per share $0.40

Broker Consensus

LGP is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Little Green Pharma Ltd (LGP) operates in the medicinal cannabis industry. Medicinal cannabis is defined as cannabis products used under recommendation by a medical professional for a defined medical condition.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office West Perth WA 6005
Website www.littlegreenpharma.com
Registry Computershare
Auditor Deloitte Touche Tohmatsu
Date Listed 20 Feb 2020

Upcoming Calendar (Forecasted)

Date Event
23/02/2022 Report (Interim)
30/08/2022 Report (Prelim)
28/09/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Alistair Warren Company Secretary Jul 2020
Dr Neale William Fong Non-Executive Director Nov 2018

Dr Neale William Fong

Non-Executive Director

Dr Fong is a registered medical practitioner with over 35 years in senior leadership roles in private hospitals, the public health systems, management consulting, academia, health research, aged care and not for profit organisations. Neale is currently CEO of Bethesda Health Care and formerly Director General of the West Australian Department of Health. Neale is also Chair of the Company's Risk Committee.

Mr Michael David Lynch-Bell Non-Executive Chairman,Non-Executive Director Nov 2018

Mr Michael David Lynch-Bell

Non-Executive Chairman,Non-Executive Director

Mr Lynch-Bell is an experienced corporate finance executive and consultant. Michael led Ernst & Young's UK IPO and Global Natural Resources transaction teams in the Transaction Advisory practice and has been involved advising companies on fundraising, re-organisations, transactions, corporate governance as well as IPOs. Michael is a former Chair of the Bureau and current member of UNECE's Expert Group on Resource Management and a Non-Executive Director of Barloworld Limited (JSE:BAW), Senior Independent Director and Remuneration Committee Chair of Gem Diamonds Limited (LSE:GEMD), Audit Committee Chair of Lenta Limited (LSE:LNTA) MCX:LNTA) and previously Deputy Chair and Nomination Committee Chair of Kaz Minerals plc.

Mr Angus McDougall Caithness Executive Director Feb 2018

Mr Angus McDougall Caithness

Executive Director

Mr Caithness is an experienced corporate finance executive and consultant in Australia and international markets. Angus acted as CFO of Tavan Tolgoi, the owner of the world's largest coking coal deposit looking at a US$10 billion dual listing in London and Hong Kong prior to the change in the Mongolian government. Angus was previously an Executive Director at Ernst & Young in London and Australia specialising in initial public offerings of large cap mining companies.

Ms Fleta Jennifer Solomon Managing Director May 2017

Ms Fleta Jennifer Solomon

Managing Director

Ms Solomon drives the strategic vision of the business and as Managing Director of Little Green Pharma has grown the company from a medicinal cannabis startup to an industryleading medicinal cannabis brand in Australia and overseas. Fleta has 20 years experience in corporate and consumer health markets.

Director Transactions

LGP directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
06/09/21 Michael Lynch-Bell Issued 70,000 $0.765 $53,550 Issue of securities
06/09/21 Neale Fong Issued 35,000 $0.765 $26,775 Issue of securities
17/08/21 Fleta Solomon Issued 1,500,000 $0.735 $1,102,500 Issue of securities
17/08/21 Angus Caithness Issued 1,500,000 $0.735 $1,102,500 Issue of securities
12/03/21 Neale Fong Issued 41,413 $0.549 $22,742 Conversion of securities
12/03/21 Neale Fong Exercise 41,413 $0.549 $22,742 Conversion of securities
12/03/21 Michael Lynch-Bell Issued 150,917 $0.70 $105,641 Conversion of securities
12/03/21 Michael Lynch-Bell Exercise 150,917 $0.70 $105,641 Conversion of securities
12/03/21 Michael Lynch-Bell Issued 82,826 $0.549 $45,485 Conversion of securities
12/03/21 Michael Lynch-Bell Exercise 82,826 $0.549 $45,485 Conversion of securities
12/03/21 Fleta Solomon Issued 40,723 $0.549 $22,363 Conversion of securities
12/03/21 Fleta Solomon Exercise 40,723 $0.549 $22,363 Conversion of securities
12/03/21 Fleta Solomon Issued 614,716 $0.70 $430,301 Conversion of securities
12/03/21 Fleta Solomon Exercise 614,716 $0.70 $430,301 Conversion of securities
12/03/21 Angus Caithness Exercise 71,782 $0.549 $39,420 Conversion of securities
12/03/21 Angus Caithness Issued 615,516 $0.70 $430,861 Conversion of securities
12/03/21 Angus Caithness Exercise 615,516 $0.70 $430,861 Conversion of securities
12/03/21 Angus Caithness Issued 71,782 $0.549 $39,420 Conversion of securities
17/12/20 Neale Fong Issued 225,458 $0.59 $133,020 Director remuneration
17/12/20 Michael Lynch-Bell Issued 450,917 $0.59 $266,041 Director remuneration
17/12/20 Fleta Solomon Issued 114,716 $0.59 $67,682 Director remuneration
17/12/20 Angus Caithness Issued 115,516 $0.59 $68,154 Director remuneration

Director Interests

The current holdings of LGP directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Michael Lynch-Bell 30/06/2021 833,743 N/A N/A N/A
Fleta Solomon 30/06/2021 20,255,439 N/A N/A N/A
Angus Caithness 30/06/2021 6,410,942 N/A N/A N/A
Neale Fong 30/06/2021 N/A 1,012,567 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Sep 16, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 41,027,331 17.40%
Elixxer Ltd 23,431,925 9.90%
Ms Fleta Jennifer Solomon 20,255,439 8.60%
Ubs Nominees Pty Ltd3 15,867,461 6.70%
Barbright Australia Pty Ltd <Interquartz Super A/C> 7,753,754 3.30%
Banquo Consulting Pty Ltd 5,500,000 2.30%
Ms Jenny Lorraine Mckay <J & K Mckay Family A/C> 2,550,044 1.10%
Benoni Pty Ltd <The Mkj Super Fund A/C 2,300,000 1.00%
Mutual Trust Pty Ltd 1,598,499 0.70%
Mr Sean Edward Reid & Ms Louise Jane Pilkington 1,552,600 0.70%
Ms Mary Bernadette Davis 1,300,000 0.60%
Heavenly Star Pty Ltd <Heavenly Star S/Fund A/C> 1,250,000 0.50%
Citicorp Nominees Pty Limited 1,169,510 0.50%
Jensen Pty Ltd 1,152,715 0.50%
Mr Damien Booth 1,025,590 0.40%
Interdale Pty Ltd <Maple Super Fund A/C> 1,009,889 0.40%
Yaselleraph Finance Pty Ltd <Yaselleraph Finance A/C> 951,938 0.40%
Mr Angus Caithness 910,942 0.40%
Mr Ean Malcolm Alexander 900,000 0.40%
Full Moon Holdings Pty Ltd <The Kosterich Family A/C> 849,195 0.40%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 2,522 4,708 1,434 1,596 145 10,405

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
HSBC Custody Nominees (Australia) Limited 16/09/2021 41,027,331 17.39
Ubs Nominees Pty Ltd 16/09/2021 15,867,461 6.73
Fleta Jennifer Solomon 16/09/2021 20,255,439 8.58
Elixxer Ltd 19/10/2021 24,710,796 10.50

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
30-06-21 Fleta Jennifer Solomon 655,439 11.10 8.70
29-06-21 TIGA Trading Pty Ltd 6,669,146 5.09 6.96
29-06-21 Bianca Hope Rinehart 26,739,029 -- 11.50
29-06-21 Georgina Hope Rinehart 26,739,029 -- 11.50
08-06-21 TIGA Trading Pty Ltd 9,531,649 -- 5.09

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
19-10-21 Elixxer Ltd 2,699,985 11.80 10.50
12-03-21 TIGA Trading Pty Ltd 7,659,010 5.70 --
22-02-21 Elixxer Ltd 739,293 20.95 15.50

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.35 30 June
LGP Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.